Drugs / UCD19
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04240808 | Jul 2020 → Mar 2023 | non-Hodgkin lymphoma | University of Colorado, Denver | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UCD19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04240808 ↗ |
| Action | Deplete | “allows the T cells to recognize and kill the lymphoma cells” NCT04240808 ↗ |
| Modality | Cell therapy | “UCD19 CAR T-cell therapy” PMID 42242517 ↗ Jun 2026 |
| Route | Intravenous | “return teh cells to the participant's body via intravenous (IV) injection” NCT04240808 ↗ |
| Target | CD19 | “CD19-directed CAR T-cell therapy” PMID 42242517 ↗ Jun 2026 |